Murdoch University Research Repository

Welcome to the Murdoch University Research Repository

The Murdoch University Research Repository is an open access digital collection of research
created by Murdoch University staff, researchers and postgraduate students.

Learn more

Abacavir hypersensitivity

Nolan, D., Almeida, C. and Phillips, E.J. (2007) Abacavir hypersensitivity. In: Pichler, W., (ed.) Drug Hypersensitivity. S. Karger AG, Basel, Switzerland, pp. 116-125.

Google Books Preview:
*Open access. Some pages may not be available


Abacavir is a commonly prescribed HIV drug belonging to the nucleoside reverse transcriptase inhibitor (NRTI) class. The major treatment-limiting side effect associated with its use is an early onset multi-system drug hypersensitivity reaction typically including some combination of rash, fever and gastrointestinal symptoms, occurring within 6 weeks of initiating treatment in approximately 5-8% of abacavir recipients. Susceptibility to this drug hypersensitivity syndrome is strongly predicted by the presence of a specific human leukocyte antigen (HLA) allele - HLA-B*5701-which represents the dominant risk factor for abacavir hypersensitivity among Caucasian and Hispanic populations. The frequency distribution of this genetic marker in different populations is likely to provide a rational basis for racially defined differences in susceptibility, while the critical role of HLA-B*5701 in directing CD8+ T-Cell-dependent, HLA-restricted immune responses provides a key role for this genetic variant in the pathogenesis of abacavir-specific immune responses. In this chapter, we review the implications of this genetic association for clinical practice as well as current knowledge of its immunological basis.

Item Type: Book Chapter
Murdoch Affiliation(s): Centre for Clinical Immunology and Biomedical Statistics
Publisher: S. Karger AG
Copyright: 2007 S. Karger
Item Control Page Item Control Page